Trials / Withdrawn
WithdrawnNCT00442923
"The Evaluation of Stimulant Withdrawal"
Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Aaron J. Janowsky · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Coreg |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2010-06-30
- Completion
- 2011-06-30
- First posted
- 2007-03-05
- Last updated
- 2019-01-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00442923. Inclusion in this directory is not an endorsement.